OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober, Laura C. Coates, Mark Lebwohl, et al.
Drug Safety (2023) Vol. 47, Iss. 1, pp. 39-57
Open Access | Times Cited: 27
Bruce Strober, Laura C. Coates, Mark Lebwohl, et al.
Drug Safety (2023) Vol. 47, Iss. 1, pp. 39-57
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 6
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 6
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, et al.
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, et al.
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN ‐FRT expert consensus
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Real‐world safety and effectiveness of guselkumab in patients with psoriasis: A post‐marketing surveillance study through up to week 52 in Japan
Yayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
The Journal of Dermatology (2025)
Open Access
Yayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
The Journal of Dermatology (2025)
Open Access
IL-23 inhibitors in psoriasis treatment: Current perspectives and emerging horizons
О. В. Жукова, S. I. Artemyeva
Meditsinskiy sovet = Medical Council (2025), Iss. 2, pp. 59-64
Open Access
О. В. Жукова, S. I. Artemyeva
Meditsinskiy sovet = Medical Council (2025), Iss. 2, pp. 59-64
Open Access
Effectiveness and Safety of Guselkumab in Patients With Moderate‐to‐Severe Plaque Psoriasis in Real‐World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study
Bong Seok Shin, Miri Kim, Moo Kyu Suh, et al.
The Journal of Dermatology (2025)
Open Access
Bong Seok Shin, Miri Kim, Moo Kyu Suh, et al.
The Journal of Dermatology (2025)
Open Access
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Laura C. Coates, Laure Gossec, Miriam Zimmermann, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003977-e003977
Open Access | Times Cited: 3
Laura C. Coates, Laure Gossec, Miriam Zimmermann, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003977-e003977
Open Access | Times Cited: 3
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
IL-23 inhibition for chronic inflammatory disease
Vipul Jairath, María Laura Acosta Felquer, Raymond J. Cho
The Lancet (2024) Vol. 404, Iss. 10463, pp. 1679-1692
Closed Access | Times Cited: 3
Vipul Jairath, María Laura Acosta Felquer, Raymond J. Cho
The Lancet (2024) Vol. 404, Iss. 10463, pp. 1679-1692
Closed Access | Times Cited: 3
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study
Piero Ruscitti, Giulia Cataldi, Martina Gentile, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 539-551
Open Access | Times Cited: 2
Piero Ruscitti, Giulia Cataldi, Martina Gentile, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 539-551
Open Access | Times Cited: 2
IL-12 family cytokines and autoimmune diseases : A potential therapeutic target?
Xue Shi Cui, Wu Liu, Hanxue Jiang, et al.
Journal of Translational Autoimmunity (2024) Vol. 10, pp. 100263-100263
Open Access | Times Cited: 2
Xue Shi Cui, Wu Liu, Hanxue Jiang, et al.
Journal of Translational Autoimmunity (2024) Vol. 10, pp. 100263-100263
Open Access | Times Cited: 2
Local injection of micro‐dose guselkumab for acrodermatitis continua of Hallopeau after failure of systemic ixekizumab treatment
YuFei Wang, ChaoJing Zhou, YiYun Hou, et al.
International Journal of Dermatology (2024) Vol. 63, Iss. 4, pp. 547-548
Closed Access | Times Cited: 1
YuFei Wang, ChaoJing Zhou, YiYun Hou, et al.
International Journal of Dermatology (2024) Vol. 63, Iss. 4, pp. 547-548
Closed Access | Times Cited: 1
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
Christopher T. Ritchlin, Philip J. Mease, Wolf‐Henning Boehncke, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 8, pp. 2551-2563
Open Access | Times Cited: 1
Christopher T. Ritchlin, Philip J. Mease, Wolf‐Henning Boehncke, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 8, pp. 2551-2563
Open Access | Times Cited: 1
IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: case series and review of literature
Natalie Bourand, Drew Kuraitis, Bethany Lema, et al.
JAAD Case Reports (2024) Vol. 56, pp. 33-37
Open Access | Times Cited: 1
Natalie Bourand, Drew Kuraitis, Bethany Lema, et al.
JAAD Case Reports (2024) Vol. 56, pp. 33-37
Open Access | Times Cited: 1
John Shi, Wei‐Yuan Chuang, Lai‐Shan Tam
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 11
Closed Access | Times Cited: 1
Neue Immunsuppressiva und das Risiko opportunistischer Infektionen
Fabian Reinhardt, Amrei von Braun, Henning Trawinski
Arthritis und Rheuma (2024) Vol. 44, Iss. 03, pp. 155-164
Closed Access
Fabian Reinhardt, Amrei von Braun, Henning Trawinski
Arthritis und Rheuma (2024) Vol. 44, Iss. 03, pp. 155-164
Closed Access
Biological gene therapy for psoriasis: more than just skin clearance
О. В. Жукова, S. I. Artemyeva
Meditsinskiy sovet = Medical Council (2024), Iss. 14, pp. 93-100
Open Access
О. В. Жукова, S. I. Artemyeva
Meditsinskiy sovet = Medical Council (2024), Iss. 14, pp. 93-100
Open Access
Guselkumab in Behçet’s disease
E Ghayad, G. Maalouf, A. Mékinian, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 12, pp. 1794-1796
Closed Access
E Ghayad, G. Maalouf, A. Mékinian, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 12, pp. 1794-1796
Closed Access
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
Philip J. Mease, Т. В. Коротаева, P. А. Shesternya, et al.
Rheumatology and Therapy (2024)
Open Access
Philip J. Mease, Т. В. Коротаева, P. А. Shesternya, et al.
Rheumatology and Therapy (2024)
Open Access
Treatment of Autoimmune Rheumatic Disease and the Risk of Malignancy
Ziga Vodusek, Clifton O Bingham, Christopher A. Mecoli
Current Treatment Options in Rheumatology (2024) Vol. 10, Iss. 4, pp. 61-76
Closed Access
Ziga Vodusek, Clifton O Bingham, Christopher A. Mecoli
Current Treatment Options in Rheumatology (2024) Vol. 10, Iss. 4, pp. 61-76
Closed Access
Infections in psoriatic arthritis: association with treatment
Athanasios Vassilopoulos, Κonstantinos Thomas, Dimitrios Vassilopoulos
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access
Athanasios Vassilopoulos, Κonstantinos Thomas, Dimitrios Vassilopoulos
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access
Prevalence of latent tuberculosis infection determined by interferon-gamma release assays in patients with immune-mediated diseases
M. Iglesias, Julia Navarro, Diana Edith Fernández Madinaveitia, et al.
Research Square (Research Square) (2024)
Open Access
M. Iglesias, Julia Navarro, Diana Edith Fernández Madinaveitia, et al.
Research Square (Research Square) (2024)
Open Access
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors
Philip J. Mease, Shannon Ferrante, Natalie J. Shiff, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 734-751
Open Access
Philip J. Mease, Shannon Ferrante, Natalie J. Shiff, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 734-751
Open Access
A Case of Allergic Contact Dermatitis Due to Chrysanthemum After Guselkumab Therapy for Palmoplantar Pustulosis
Mari Kishibe, Sawa Ohtsubo, Satomi Igawa, et al.
Cureus (2024)
Open Access
Mari Kishibe, Sawa Ohtsubo, Satomi Igawa, et al.
Cureus (2024)
Open Access
